Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05595486
Other study ID # STU00216659
Secondary ID 1R01HD105499-01
Status Recruiting
Phase N/A
First received
Last updated
Start date November 9, 2022
Est. completion date March 1, 2025

Study information

Verified date July 2023
Source Women and Infants Hospital of Rhode Island
Contact Joshua Santiago, MA
Phone 3125032596
Email joshua.santiago@northwestern.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The COVID-19 pandemic has transformed healthcare delivery; arguably, the fields of obstetrics and pediatrics have experienced some of the greatest changes as they have transitioned away from their role as a medical home and into more of an urgent care model of care. Baby2Home is a digital health intervention designed to bridge the resultant gaps in obstetrics and pediatrics healthcare services for new families over the first year of life. This randomized controlled trial will evaluate whether, compared to usual care, Baby2Home 1) improves maternal, paternal, and infant health service utilization outcomes over the first year postpartum, 2) improves maternal and paternal patient reported outcomes, and 3) reduces racial/ethnic and income-based disparities in preventive health services utilization and parental patient reported outcomes.


Description:

The transition to new parenthood is marked by dramatic changes in social roles and responsibilities. To support new parents, obstetric and pediatric healthcare surrounding this transition is designed with a supportive focus to facilitate new parents' navigation of the attendant life changes. The COVID-19 pandemic has altered healthcare delivery in ways that have limited these supportive obstetrics and pediatric services provided at the beginning of new parenthood. Consequently, aspects of preventative healthcare, such as monitoring for symptoms of postpartum depression, discussing optimal birth control options, educating parents on recommended adult and pediatric vaccinations, and providing anticipatory guidance on infant wellness, are less robust. In addition, without professional guidance and support, outcomes of foundational importance to new parents, such as perceived stress, depressive and anxiety symptoms, or parenting and breast-feeding self-efficacy, are worse. Moreover, the COVID-19 pandemic has underscored the impact of the social determinants of health on new family wellness, with racial/ethnic minority and low-income families being differentially impacted by COVID-19 pandemic driven healthcare delivery changes. Recognizing the potential for longitudinal changes in healthcare delivery engendered by the COVID-19 pandemic, a scalable, patient-centered, equity-focused intervention designed to bridge gaps in healthcare services around the transition to new parenthood is needed. "Bridging gaps in healthcare delivery to COVID-19 for parent and infants from birth through the first year of life" aims to evaluate Baby2Home (B2H) a patient-informed digital healthcare intervention that s is specifically responsive to the COVID-19 pandemic's impact on new families, with a focus on health equity for racial/ethnic minority and low-income families. B2H builds upon previous digital health successes while incorporating the evidence-based collaborative care model for mental health support. B2H is designed to mitigate the adverse effects of healthcare delivery changes in response to the COVID-19 pandemic and to improve health for mothers, fathers, and infants over the first year of life. Developed from feedback given by new parents who delivered during the COVID-19 pandemic, B2H provides 1) parental education about their own physical and mental health, 2) infant wellness resources and tracking of recommended healthcare services, 3) parental mental health screening and support, and 4) systematic case review to optimize the health of new families. The investigators will test the efficacy of B2H via a randomized control trial. In total, 640 diverse families will be randomly to either usual care or B2H intervention arm to evaluate whether, compared to usual care, B2H health services utilization and patient reported outcomes of foundational important to new families. addition, the investigators will evaluate the impact of B2H on racial/ethnic and income-based disparities observed in both services utilization and patient reported outcomes.


Recruitment information / eligibility

Status Recruiting
Enrollment 640
Est. completion date March 1, 2025
Est. primary completion date December 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Delivery at Prentice Women's Hospital or Women and Infants Hospital of Rhode Island - Viable term infant (= 37 weeks) - First live born child - English speaking - Age 18 years old or greater - Access to a smartphone - Access to a working email address Exclusion Criteria: - No smartphone access - Infant death - Infant requires NICU admission - Known severe mental illness of either parent (e.g., bipolar disorder, schizophrenia) - SARS-CoV-2 infection without clinical clearance - History of IPV (intimate partner violence) with current partner (would exclude partner) - Concurrent enrollment in studies that may affect the outcome of the trial (or vice versa)

Study Design


Intervention

Other:
Baby2Home Mobile Application
Baby2Home is a digital health intervention designed to bridge the resultant gaps in obstetrics and pediatrics healthcare services for new families over the first year of life.

Locations

Country Name City State
United States Northwestern Medicine Prentice Women's Hospital Chicago Illinois
United States Women and Infant's Hospital Providence Rhode Island

Sponsors (2)

Lead Sponsor Collaborator
Women and Infants Hospital of Rhode Island Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Concentration of preventive health services utilization for all family members (birthing, non-birthing, and infant) The primary outcome defined as positive if all of the items below are met for all family members:
optimal maternal preventive health services utilization over the 1st year postpartum (including attendance at the comprehensive postpartum visit, receives chosen contraceptive method, and undergoes postpartum depression screening and, if depression is suspected, receives a recommendation for treatment)
optimal paternal/co-parental preventive health services utilization over the 1st year postpartum (including receiving recommended vaccinations for new parents, if desires a male-driven contraceptive option, receives chosen method, and undergoes screening for depression and, if depression is suspected, receives recommendation for treatment)
optimal infant preventive health services utilization over the 1st year postpartum (including attending all AAP recommended wellness visits, receiving all AAP recommended vaccines, and receiving breast milk for 6 months of life)
Baseline through 1 year postpartum
Secondary Number of participants who attend comprehensive postpartum visit (birthing parent) Subject returns for a comprehensive medical care at least once between 4 and 12 weeks postpartum. This visit should include documented elements of physical health, mood, mode of infant feeding, contraception, preventive health, and any comorbidities. At least once between 4 and 12 weeks postpartum
Secondary Completion of postpartum depression screening and treatment (birthing parent) Subject completes a validated screen for postpartum depression and, if the screen is positive, receives a recommendation for treatment. To assess depressive symptoms, birthing will take the 9-item Patient Health Questionnaire (PHQ). This is scored on a Likert-type scale from 0 - 3 (Not at all to Nearly everyday). A lower score reflects minimal depression and a higher score reflects severe depression. Through study completion, up to 12 months
Secondary Number of participants who received contraception (birthing and non-birthing parent) If a subject desires a contraceptive method, they receives chosen method. Receipt of contraception can be an actual insertion of device (implant or IUD), receipt of injection, receipt of sterilization (BTL or vasectomy, if vasectomy is confirmed to have been performed), or prescription for a combined hormonal contraceptive method. Through study completion, up to 12 months
Secondary Number of participants who received the recommended vaccinations (non-birthing parent) Subject receives influenza and TDaP vaccines before 12 months postpartum. Through study completion, up to 12 months
Secondary Completion of postnatal depression screening for non-birthing parent Subject completes a validated screen for depression and, if the screen is positive, receives a recommendation for treatment. To assess depressive symptoms, non-birthing parents will take the 9-item Patient Health Questionnaire (PHQ). This is scored on a Likert-type scale from 0 - 3 (Not at all to Nearly everyday). A lower score reflects minimal depression and a higher score reflects severe depression. Through study completion, up to 12 months
Secondary Number of participants who attended well-child visits for the infant Subject attends all AAP recommended wellness visits. Attendance at each visit will be derived from both patient-report (via B2H) and through ROIs from the pediatrician offices. Preference will be given to the ROIs, but if this not available, patient-report will be used as equal. If these data points are conflicting, patient-report will supersede the medical record. Through study completion, up to 12 months
Secondary Number of participants who received the recommended vaccinations for infant Subject receives all AAP recommended vaccinations. This information will be ascertained from the ROIs from the pediatrician offices. Recognizing various vaccine schedules, this will be determined as a binary variable at 12 months postpartum (and the % of vaccines received). Through study completion, up to 12 months
Secondary Continued breastfeeding for infants until 6 months. This outcome will be patient-reported. The investigators will evaluate this outcome as positive if breastmilk is a source of nutrition until 6 months.
The primary analysis will be of all subjects who were eligible for breastfeeding (i.e., excluding those unable to breastfeed due to a medical complication). Investigators will perform secondary analyses in which individuals who do not desire breastfeeding and did not initiate breastfeeding will not be considered in this component of outcomes.
Through study completion, up to 6 months
Secondary Duration of breastfeeding (birthing parent) This outcome will be patient-reported. The investigators will also evaluate as an ordinal outcome of total duration (months) of any breastfeeding and total duration (months) of exclusive breastfeeding.
The primary analysis will be of all subjects who were eligible for breastfeeding (i.e., excluding those unable to breastfeed), but the investigators will perform secondary analyses in which individuals who do not desire breastfeeding and did not initiate breastfeeding will not be considered in this component of outcomes.
Through study completion, up to 6 months
Secondary Stress symptoms (for birthing and non-birthing parent) To assess stress, birthing and non-birthing parents will take the 10-item Perceived Stress Scale (PSS). This is scored on a Likert-type scale from 0 - 4 (Never to Very often). Individual scores on the PSS can range from 0 to 40 with higher scores indicating higher perceived stress. Month 1, 2, 4, 6, and 12
Secondary Depressive symptoms (for birthing and non-birthing parent) To assess depressive symptoms, birthing and non-birthing parents will take the 9-item Patient Health Questionnaire (PHQ). This is scored on a Likert-type scale from 0 - 3 (Not at all to Nearly everyday). A lower score reflects minimal depression and a higher score reflects severe depression. Month 1, 2, 4, 6, and 12
Secondary Anxiety symptoms (for birthing and non-birthing parent) To assess anxiety, birthing and non-birthing parents will take the 7-item Generalized Anxiety Disorder Scale. This is scored on a Likert-type scale from 0 - 3 (Not at all to Nearly everyday). A lower score reflects minimal anxiety and a higher score reflects severe anxiety. Month 1, 2, 4, 6, and 12
Secondary Global health status (for birthing and non-birthing parent) To assess health status, birthing and non-birthing parents will take the 10-item PROMIS Global Health Scale. This is scored on a Likert-type scale from 5 - 1 (Excellent to Poor). A higher score indicates better health status. Month 1, 2, 4, 6, and 12
Secondary Relationship assessment (for birthing and non-birthing parent) To assess relationship status, birthing and non-birthing parents will take the 14-item Revised Dyadic Adjustment Scale (RDAS). This is scored on a Likert-type scale from 0 - 5 (Everyday to Never). Scores on the RDAS range from 0 to 69 with higher scores indicating greater relationship satisfaction and lower scores indicating greater relationship distress. The cut-off score for the RDAS is 48 such that scores of 48 and above indicate non-distress and scores of 47 and below indicate marital/relationship distress. Month 1, 2, 4, 6, and 12
Secondary Self-efficacy (for birthing and non-birthing parent) To assess self-efficacy, birthing and non-birthing parents will take the 10-item PROMIS Self-Efficacy Scale. This is scored on a Likert-type scale from 1 - 5 (I am not at all confident to I am very confident). A higher score indicates a higher sense of general self-efficacy. Month 1, 2, 4, 6, and 12
Secondary Parenting self-efficacy (for birthing and non-birthing parent) To assess parenting self-efficacy, birthing and non-birthing parents will take the 17-item Parenting Sense of Competence Scale. This is scored on a Likert-type scale from 1 - 6 (Strongly Disagree to Strongly Agree). A higher score indicates a higher parenting sense of competency. Month 1, 2, 4, 6, and 12
Secondary Breastfeeding self-efficacy (for birthing parent) To assess breastfeeding self-efficacy, birthing parents will take the 12-item Breastfeeding Self-Efficacy scale. This is scored on a Likert-type scale from 1 - 7 (Strongly Disagree to Strongly Agree). A higher score indicates a better/more positive outcome towards breastfeeding. Month 1, 2, 4, 6, and 12
Secondary COVID-19 related impact (for birthing and non-birthing parent) To assess the impact of COVID-19, birthing and non-birthing parents will take the 10-item Coronavirus Impact Scale (CIS). This scale is rated from 0 - 3 (no change, mild change, moderate change, and severe change). A higher score indicates a worse outcome for the Coronavirus Impact in a participant's life. Month 1, 2, 4, 6, and 12
See also
  Status Clinical Trial Phase
Completed NCT05197634 - The Impact of Covid-19 Pandemic On The Children With Autism Spectrum Disorder
Recruiting NCT05918939 - UNAIR Inactivated COVID-19 Vaccine as Heterologue Booster (Immunobridging Study) Early Phase 1
Completed NCT05383560 - Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults Phase 2
Active, not recruiting NCT05125874 - Clinical Study for Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Immunization N/A
Completed NCT05517148 - Effects of an Immersive Virtual Reality Intervention Combined With Mindfulness-based Stress Reduction N/A
Completed NCT05552989 - Towards Better Preparedness for Future Catastrophes - Local Lessons-learned From COVID-19
Completed NCT05543551 - Effects of Diagrammatic Breathing With and Without Resistance in Post Covid Patients on ADLs N/A
Active, not recruiting NCT06272253 - UNAIR Inactivated COVID-19 Vaccine INAVAC as Heterologue Booster (Immunobridging Study) in Adolescent Subjects Early Phase 1
Active, not recruiting NCT05585567 - A Preliminary Exploratory Study to Evaluate the Safety and Immunogenicity of Omicron Variant Bivalent Vaccine V-01-B5 Early Phase 1
Active, not recruiting NCT05582746 - COVID-19 Testing and Vaccine Literacy for Women With Criminal Legal System Involvement N/A
Not yet recruiting NCT05381883 - Mental Health of Professionals of the Silver Economy of New Aquitaine : Online Survey of Accommodation Establishments for Old People and Home Assistance Establishments N/A
Recruiting NCT05062681 - RCT on the Efficacy of Dexamethasone Versus Methyl Prednisolone in Covid-19 Infected Patients With High Oxygen Flow Phase 4
Completed NCT04697030 - Burnout Among Adolescent Population During Covid-19 Lockdown in Pakistan
Active, not recruiting NCT05419167 - STEP-COVID: A Program for Pregnant Women During the SARS-CoV-2 Pandemic Phase 1
Terminated NCT05553964 - SARS-CoV-2 OTC At Home Test N/A
Completed NCT05596032 - Prospective Study to Validate the Diagnostic Performance of IVD CAPSULE COVID-19-NP Test for the Detection of SARS-CoV-2
Completed NCT05583812 - A Study of FB2001 for Inhalation in Healthy Chinese Adults Phase 1
Completed NCT05844410 - Evaluation of Corticosteroids Use and Clinical Outcomes in Hospitalized COVID-19 Patients: A Retrospective Study
Completed NCT05123573 - Self-Perceived in Medical Students Undergoing Distance Learning
Completed NCT05305300 - A Phase I Study to Evaluate Safety, Tolerability, and Immunogenicity of a PIKA COVID-19 Vaccine in Healthy Individuals Phase 1